Pdr5: A master of asymmetry.

ABC transporter Asymmetry Fungal resistance Multidrug resistance Pdr5

Journal

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
ISSN: 1532-2084
Titre abrégé: Drug Resist Updat
Pays: Scotland
ID NLM: 9815369

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 30 05 2023
revised: 05 10 2023
accepted: 05 10 2023
medline: 21 11 2023
pubmed: 20 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

Pdr5 is a founding member of a large (pdr) subfamily of clinically and agriculturally significant fungal ABC transporters. The tremendous power of yeast genetics combined with biochemical and structural approaches revealed the astonishing asymmetry of this efflux pump. Asymmetry is manifested in Pdr5's ATP-binding sites, drug binding sites, signal transformation interface, and molecular exit gate. Even its mode of conformational switching is asymmetric with one half of the protein remaining nearly stationary. In the case of its ATP-binding sites, asymmetry is created by replacing a set of highly conserved residues with a characteristic set of deviant ones. This contrasts with the asymmetry of the molecular gate. There, a full complement of canonical residues is present, but structural features in the vicinity prevent some of these from forming a molecular plug during closure. Compared to their canonical-functioning counterparts, the deviant ATP site and these gating residues have different, essential functions. In addition to its remarkable asymmetry, the surprising observation that Pdr5 is a drug / proton co-transporter shines a new light on this remarkable protein.

Identifiants

pubmed: 37862721
pii: S1368-7646(23)00093-6
doi: 10.1016/j.drup.2023.101010
pii:
doi:

Substances chimiques

ATP-Binding Cassette Transporters 0
Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101010

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

John Golin (J)

The Department of Biology, Stern College for Women, Yeshiva University, New York, NY 10016, USA. Electronic address: golin@cua.edu.

Lutz Schmitt (L)

Institute of Biochemistry, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH